KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Amortization of Deferred Charges (2017 - 2025)

Historic Amortization of Deferred Charges for Emergent BioSolutions (EBS) over the last 9 years, with Q3 2025 value amounting to $2.5 million.

  • Emergent BioSolutions' Amortization of Deferred Charges rose 13731.34% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 1376.15%. This contributed to the annual value of $7.4 million for FY2024, which is 6525.82% down from last year.
  • As of Q3 2025, Emergent BioSolutions' Amortization of Deferred Charges stood at $2.5 million, which was up 13731.34% from $2.4 million recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Amortization of Deferred Charges high stood at $8.9 million for Q2 2023, and its period low was -$6.7 million during Q3 2024.
  • Its 5-year average for Amortization of Deferred Charges is $2.3 million, with a median of $1.1 million in 2021.
  • In the last 5 years, Emergent BioSolutions' Amortization of Deferred Charges skyrocketed by 79000.0% in 2023 and then tumbled by 21754.39% in 2024.
  • Emergent BioSolutions' Amortization of Deferred Charges (Quarter) stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then soared by 470.0% to $5.7 million in 2023, then tumbled by 61.4% to $2.2 million in 2024, then grew by 13.64% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.4 million for Q2 2025, and $2.3 million during Q1 2025.